×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Brain Cancer

Feature Video
Watch a video about Steve, an Optune user. Learn how Steve manages his treatment while enjoying his favorite activities.
Lori Luedtke
Four out of 100. That is the survival rate for stage 4 glioblastoma: four percent. 
Jeannine Walston
Learn about awareness and actions strategies during Brain Tumor Awareness Month and beyond.
Alexandra Guadagno
From the first annual Glioblastoma Awareness Day to politics and today’s top performers, here’s what’s making headlines in the cancer space this week.​
Samira Rajabi
Carrying chronic illness can be very difficult, but there are ways to navigate the world without being crushed by the weight of what we cannot control.
Kristie L. Kahl
Children diagnosed with embryonal brain tumors who have experienced treatment-related hearing loss exhibited greater difficulties reading – in particular, with phonological skills and processing speed, according to study results.
Alexandra Guadagno
From National Women's Health Week to today’s top athletes, here’s what’s making headlines in the cancer space this week.
Alexandra Guadagno
The phase 3 CheckMate 498 trial, designed to compare Opdivo with Temodal for the treatment of patients with newly diagnosed O6-methylguanine-DNA methyltransferase (MGMT)-unmethylated glioblastoma multiforme failed to meet its primary endpoint of increasing overall survival.
Alexandra Guadagno
From a sweet fundraiser for breast cancer to today’s top performers and athletes, here’s what’s making headlines in the cancer space this week.
Beth Fand Incollingo
Evaluations can identify the potential for drug interactions and predict whether older patients are fit for chemotherapy.
Katie Kosko
Researchers examine genomic mutations with tumor response to Keytruda and Opdivo in patients with GBM, highlighting the potential for a molecular, personalized approach to treat certain patients.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

Patient Caregiver Advocate Other